Table 1.
Anxiety, depression, stress, well‐being, and insomnia severity at baseline, mid‐intervention, post‐intervention, and follow‐up
| Outcome | T1: Baseline | T2: Mid‐Intervention | T3: Post‐Intervention | T4: 6 Month Follow‐Up | Effects Time × Group | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| iMBCT | Control | iMBCT | Control | iMBCT | Control | iMBCT | Control | T1‐T3: Baseline–post intervention, Cohen d (95%CI); P | T1‐T4: Baseline–follow‐up (6 months), Cohen d (95% CI); P | |
| N | 104 | 46 | 77 | 38 | 73 | 38 | 74 | 37 | ||
| Primary outcomes (means and SDs) | ||||||||||
| STAI‐Y | 41.7 (10.2) | 42.7 (9.8) | 40.2 (9.2) | 42.7 (9.6) | 37.5 (8.9) | 41.8 (11.9) | 36.3 (9.9) | 40.5 (11.9) | 0.45 (0.26‐0.64); .017 | 0.40 (0.00‐0.80); .029 |
| BDI‐II | 15.1 (7.4) | 17.6 (7.5) | 11.9 (8.3) | 15.0 (8.4) | 10.7 (6.6) | 15.6 (9.2) | 10.2 (7.9) | 14.2 (9.7) | 0.42 (0.23‐0.61); .024 | 0.28 (0.09‐0.47); .131 |
| Secondary outcomes (means and SDs) | ||||||||||
| PSS | 18.5 (5.7) | 18.9 (6.2) | 16.7 (6.0) | 17.5 (6.1) | 15.7 (5.9) | 17.0 (6.3) | 15.0 (6.6) | 17.1 (6.8) | 0.18 (−0.21 to 0.57); .331 | 0.29 (−0.11 to 0.69); .125 |
| WHO‐5 | 17.6 (4.8) | 17.8 (5.4) | N/A | 15.6 (4.7) | 16.5 (5.0) | 15.0 (5.2) | 17.1 (5.6) | 0.25 (−0.14 to 0.64); .173 | 0.48 (0.08‐0.88); .010 | |
| ISI | 11.7 (5.5) | 11.8 (6.3) | N/A | 10.3 (6.0) | 10.1 (6.9) | 10.1 (6.3) | 10.0 (6.3) | 0.06 (−0.33 to 0.45); .759 | 0.04 (−0.36 to 0.44); .847 | |
Note. N = number of participants who filled out questionnaires at the given time point.